Semaglutide Cost by State: What You'll Actually Pay in 2026

Why Semaglutide Cost Depends on Your State

Semaglutide (the molecule behind Wegovy and Ozempic) carries a list price north of $1,000 a month. Almost nobody actually pays that — but what you do pay hinges on coverage, and Medicaid coverage is set state by state. That's because Medicaid is a joint federal-state program: while the federal Medicaid Drug Rebate Program forces states to cover most FDA-approved drugs, there's one loophole that matters here — states are not obligated to cover anything prescribed for weight loss.

For years, that loophole kept anti-obesity medications (AOMs) like Wegovy and Zepbound off most state formularies, leaving residents on the hook for the full cash price. That picture is changing fast:

• The Treat and Reduce Obesity Act and related federal efforts keep nudging states toward adding coverage
• Mounting evidence that GLP-1 drugs cut cardiovascular risk has let several states cover them under heart-health indications rather than "weight loss"
• CMS guidance from late 2025 urged — but stopped short of requiring — states to add GLP-1 coverage
• A wave of states either added or widened coverage across 2025–2026

And "covered" doesn't mean the same thing everywhere. Some states only pay for semaglutide when it's prescribed for diabetes. Others cover it for obesity but bury it under tough prior-authorization rules (BMI 40+, or BMI 35+ with comorbidities). A handful cover it generously at the standard obesity threshold (BMI 30+). Where you fall on that spectrum is, in practice, your semaglutide cost.

States Where Semaglutide Costs You Least

If you live in one of the states below, you've hit the jackpot on semaglutide cost — their Medicaid programs offer the most generous GLP-1 obesity coverage in the country as of April 2026, often dropping your out-of-pocket to a standard copay:

States Where You Pay Cash for Semaglutide

Here's the flip side. As of April 2026, 14 stateswon't put a dime toward any GLP-1 prescribed for obesity through Medicaid — meaning your semaglutide cost lands squarely on you. These states will often still cover Ozempic or Mounjaro for a documented type 2 diabetes diagnosis, just not for weight management:

If you live in one of these states, your options for affordable GLP-1 access include:

• Patient assistance programs: NovoCare (Wegovy) and Lilly Cares (Zepbound) provide free medication for income-qualified patients regardless of state
• LillyDirect: Zepbound at $349/month, available nationwide
• Oral Wegovy: $149/month at lowest dose, available at retail pharmacies
• Appeal: If you have a weight-related condition (cardiovascular disease, sleep apnea, type 2 diabetes), your doctor may be able to obtain coverage under a medical necessity exception

How to Check Your State's Coverage

State formularies get rewritten constantly, so treat the table above as a snapshot from our April 2026 research rather than gospel. Before you assume a number, confirm what semaglutide will actually cost you in your state with these four steps:

1. Contact your Medicaid managed care plan directly. Most states contract with multiple managed care organizations (MCOs), and each may have different formulary rules. Call the number on the back of your Medicaid card.
2. Search your state's preferred drug list (PDL).Most states publish their Medicaid formulary online. Search for "[your state] Medicaid preferred drug list" and look for semaglutide, tirzepatide, Wegovy, or Zepbound.
3. Ask your prescriber to submit a prior authorization. Even in states without formulary coverage, some patients obtain approval through medical necessity exceptions, especially if they have cardiovascular disease, type 2 diabetes, or sleep apnea.
4. Contact a patient advocacy organization. The Obesity Action Coalition (OAC) maintains resources for navigating insurance coverage for weight management medications.

Medicare Coverage for 65+

If you are 65 or older, Medicaid coverage may be less relevant — Medicare is your primary insurance. Starting July 2026, Medicare Part D will cover Wegovy and Zepbound for obesity through a Bridge program:

• Estimated copay: $50/month
• Eligibility: BMI 30+ or BMI 27+ with weight-related condition
• Covered medications: Wegovy (injectable and oral), Zepbound
• Prior authorization: Required

For dual-eligible patients (those on both Medicare and Medicaid), Medicare Part D will be the primary payer for GLP-1 medications starting July 2026. This is a significant improvement for low-income seniors who currently have no coverage path.

Read our complete Medicare GLP-1 Coverage Guide for details on enrollment, eligibility, and how to prepare.